Healthcare / Drug Manufacturers - Specialty & GenericBSE
$7.50
-0.05 (-0.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-23.5M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
12/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$76M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-22.2%
↓Gross Margin
97.0%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-29.8%
FCF CAGR
—
FCF margin
-43.7%
FCF / Net income
1.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $226.1M · net income $-50.8M · FCF $-98.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $226.1M | $226.1M | $358.8M | $455.7M | $653.2M |
| Net Income | $-50.8M | $-50.8M | $-16.8M | $-26.8M | $113.8M |
| EBITDA | $-59.1M | $-59.1M | $-5.4M | $-33.0M | $137.0M |
| EPS | -5.03 | -5.03 | -1.66 | -2.66 | 11.27 |
| Gross Margin | 97.0% | 97.0% | 91.3% | 98.9% | 99.8% |
| Operating Margin | -9.2% | -9.2% | -0.8% | -4.9% | 19.2% |
| Net Margin | -22.5% | -22.5% | -4.7% | -5.9% | 17.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | — | 0.04 | 0.43 |
| Cash Flow | |||||
| Free Cash Flow | $-98.8M | $-98.8M | $48.0M | $-23.5M | $80.7M |
| Returns | |||||
| ROE | -22.2% | -22.2% | -7.7% | -11.6% | 47.1% |
| Valuation | |||||
| P/E | — | — | — | — | 5.30 |
| EV/EBITDA | — | — | — | — | 4.03 |
| P/B | 0.33 | 0.33 | 0.77 | 0.84 | 2.50 |
| Growth & Yield | |||||
| Revenue Growth | -37.0% | -37.0% | -21.3% | -30.2% | — |
| EPS Growth | -203.0% | -203.0% | 37.6% | -123.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.66 → -5.03
Residual
-37.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.